아시아태평양의 트랜스페션 시약 및 기기 시장 예측(-2030년) : 지역별 분석 - 제품, 방법, 용도, 최종사용자별

Asia Pacific Transfection Reagents and Equipment Market Forecast to 2030 - Regional Analysis - by Product, Method, Application, and End User

US $ 3,450 ￦ 4,989,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450 ￦ 6,436,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,450 ￦ 7,882,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

아시아태평양의 트랜스페션 시약 및 장비 시장은 2022년에 2억 2,223만 달러로 평가되며, 2030년에는 4억 1,429만 달러에 달할 것으로 예상되며, 2022년부터 2030년까지 8.1%의 CAGR을 기록할 것으로 예상됩니다.

암의 경제적 부담 증가로 아시아태평양 이식 시약 및 장비 시장 성장 촉진

세계보건기구(WHO)에 따르면 암은 전 세계 주요 사망 원인 중 하나이며, 2020년 사망자 수는 1,000만 명에 달할 것으로 예상됩니다. 국제 암 연구 기관에 따르면 2040년까지 3,020 만 건의 사례가 추가되어 전 세계 암 부담이 증가할 가능성이 높습니다. 국제유방암기구에 따르면 전 세계 유방암 환자의 약 5-10%는 유전적 요인으로 대대로 물려받은 비정상적인 유전자로 인해 발생하며, 2023년 International Journal of Epidemiology에 게재된 논문 'Lifestyle, Genetic Risk and Incidence of Cancer' 논문에 따르면, 발생하는 암 질환의 33% 가량이 유전성이며, 유전자 변이 위험이 높은 질환입니다. 따라서 사람들은 유전성 암의 조기 발견과 맞춤 치료를 위해 유전자 프로파일링을 선택하고 있으며, BRCA1과 BRCA2는 종양 억제 유전자로 불리기도 합니다. 이 유전자의 유해한 변이체를 물려받은 사람은 일부 암, 특히 유방암과 난소암에 걸릴 위험이 높습니다. 또한 이러한 사람들은 해당 유전자에 돌연변이가 없는 사람들에 비해 젊은 나이에 암이 발병하는 경향이 있습니다. 암세포의 핵산 처리에 초점을 맞춘 연구는 암의 대사를 이해하는 데 도움이 될 수 있으며, DNA는 일반적으로 바이러스 또는 비바이러스성 입자에 포장되어 세포에 도입되어 세포 내로 도입됩니다. 유전자 도입은 난치성 및 전이성 암 치료에서 항종양제의 효과를 높이는 새로운 접근법으로 제안되고 있습니다. 폐암, 대장암, 췌장암, 방광암, 유방암 등에서는 유전자 치료와 약물의 병용요법(유사 요법)을 통해 기존 치료법의 항증식 효과가 증강되는 것으로 보고되고 있습니다. 이처럼 암에 대한 경제적 부담이 증가함에 따라 아시아태평양의 유전자 전달 시약 및 기기 시장이 강화되고 있습니다.

아시아태평양 트랜스페션 시약 및 장비 시장 개요

아시아태평양은 중국, 일본, 인도, 한국, 호주, 기타 아시아태평양으로 분류되며, 2022년에는 중국이 가장 큰 시장 점유율을 차지했습니다. 중국, 인도, 싱가포르 등 아시아태평양 국가는 의료 시스템이 잘 구축되어 있고 제약 및 의료 산업도 빠르게 성장하고 있습니다. 이들 국가에는 암 환자에게 치료 및 치료 서비스를 제공하는 많은 의료 시설이 있으며, NIH의 조사에 따르면 중국의 암 병원의 연간 입원 환자 수는 2010년부터 2020년까지 110만 명에서 324만 명으로 증가했습니다. American Medical Association에 발표된 연구에 따르면 중국 본토의 18세 이상 만성신장병(CKD) 유병률은 8.2%에 달합니다. 또한 국제암연구소(IARC)의 최신 데이터에 따르면 중국 위암의 추정 연령 표준화율(ASR)은 10만 명당 21명, 조사율은 33.06명, 췌장암의 ASR은 10만 명당 5명, 조사율은 8.6명입니다. 같은 자료에 따르면 2020년 0-74세 위암과 췌장암 신규 환자 수(남녀 모두)는 각각 47만 8,508명, 12만 4,994명으로 추정됩니다. 이러한 만성질환의 높은 부담은 중국 내 CGT에 대한 수요를 촉진하고, 이는 곧 이식 시약 및 기기 시장의 성장에 박차를 가하고 있습니다.

아시아태평양 트랜스페션 시약 및 장비 시장 매출 및 2030년까지의 예측(금액)

아시아태평양 트랜스페션 시약 및 장비 시장 세분화

아시아태평양 트랜스페션 시약 및 장비 시장은 제품, 방법, 용도, 최종사용자, 국가별로 세분화되어 있습니다.

제품별로는 아시아태평양의 트랜스페션 시약 및 장비 시장은 시약과 장비로 나뉩니다. 시약 부문은 2022년 큰 비중을 차지했습니다.

기법별로 아시아태평양의 트랜스페션 시약 및 기기 시장은 바이러스성 방법, 비바이러스성 방법, 하이브리드 방법으로 구분되며, 2022년에는 비바이러스성 방법이 가장 큰 비중을 차지했습니다. 바이러스 방식은 레트로바이러스, 아데노바이러스, 아데노 관련 바이러스, 헤르페스 바이러스로 분류됩니다. 비바이러스성 부문은 물리적/기계적 방법과 화학적 방법으로 나뉩니다. 또한, 물리적/기계적 방법은 일렉트로포레이션법, 마이크로 인젝션법, 바이오리스틱법, 레이저법, 마그네토펙션법, 소노포레이션법으로 세분화됩니다. 또한, 화학적 방법 부문은 리포좀 기반/고지질 기반과 비리포좀/고지질 기반으로 세분화됩니다.

용도별로 아시아태평양의 트랜스페션 시약 및 기기 시장은 바이오메디컬 연구, 단백질 생산, 치료 전달로 구분됩니다. 바이오 의학 연구 부문이 2022년 가장 큰 점유율을 차지했습니다.

최종사용자별로 보면 아시아태평양의 트랜스페션 시약 및 기기 시장은 학술 및 연구 기관과 제약 및 생명공학 기업으로 양분되며, 2022년에는 학술 및 연구 기관 부문이 더 큰 점유율을 차지했습니다.

국가별로 보면 아시아태평양의 트랜스페션 시약 및 장비 시장은 호주, 중국, 인도, 일본, 한국 및 기타 아시아태평양으로 분류됩니다. 중국이 2022년 아시아태평양 이식 시약 및 장비 시장을 장악했습니다.

Fisher Scientific Inc, Promega Corp, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Virus Bio LLC, QIAGEN NV, Merck KGaA, Lonza Group AG, MaxCyte Inc, Polyplus-Transfection SA, MaxCyte Inc, Polyplus-Transfection SA는 아시아태평양 트랜스페션 시약 및 장비 시장에서 활동하는 주요 기업입니다.

목차

제1장 소개

제2장 주요 요약

• 주요 인사이트

제3장 조사 방법

• 조사 범위
• 2차 조사
• 1차 조사

제4장 아시아태평양의 트랜스펙션 시약 및 장비 시장 - 주요 시장 역학

• 아시아태평양의 트랜스펙션 시약 및 장비 시장 : 주요 시장 역학
• 시장 성장 촉진요인
  • 세포 치료와 유전자 치료의 인기 상승
  • 암의 경제적 부담 증대
• 시장 성장 억제요인
  • 기기 및 소모품의 고비용
• 시장 기회
  • 소규모 프로세스에서 대규모 프로세스로의 확대
• 향후 동향
  • 기업의 전략적 대처
• 성장 촉진요인과 억제요인의 영향

제5장 트랜스펙션 시약 및 장비 시장 : 아시아태평양 시장 분석

• 아시아태평양의 트랜스펙션 시약 및 장비 시장 매출, 2022-2030년
• 아시아태평양의 트랜스펙션 시약 및 장비 시장 예측 분석

제6장 아시아태평양의 트랜스펙션 시약 및 장비 시장 분석 : 제품별

• 시약
• 장비

제7장 아시아태평양의 트랜스펙션 시약 및 장비 시장 분석 : 모달리티별

• 바이러스
• 비바이러스
• 하이브리드

제8장 아시아태평양의 트랜스펙션 시약 및 장비 시장 분석 : 용도별

• 바이오메디컬 연구
• 단백질 생산
• 치료 딜리버리

제9장 아시아태평양의 트랜스펙션 시약 및 장비 시장 분석 : 최종사용자별

• 학술·연구기관
• 제약·바이오테크놀러지 기업

제10장 아시아태평양의 트랜스펙션 시약 및 장비 시장 : 국가별 분석

• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 기타 아시아태평양

제11장 트랜스펙션 시약 및 장비 시장 : 업계 상황

• 트랜스펙션 시약 및 장비 시장의 성장 전략, 2020-2023년
• 무기적 성장 전략
• 유기적 성장 전략

제12장 기업 개요

• Thermo Fisher Scientific Inc
• Promega Corp
• F. Hoffmann-La Roche Ltd
• Bio-Rad Laboratories Inc
• Mirus Bio LLC
• QIAGEN NV
• Merck KGaA
• Lonza Group AG
• MaxCyte Inc

제13장 부록

ksm

영문 목차

영문목차

The Asia Pacific transfection reagents and equipment market was valued at US$ 222.23 million in 2022 and is expected to reach US$ 414.29 million by 2030; it is estimated to register at a CAGR of 8.1% from 2022 to 2030.

Growing Economic Burden of Cancer Boosts Asia Pacific Transfection Reagents and Equipment Market

According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, and it accounted for ~10 million deaths in 2020. As per the International Agency for Research on Cancer, the global cancer burden is likely to increase with the addition of 30.2 million more cases by 2040. According to the Breast Cancer Organization, approximately 5-10% of breast cancer cases worldwide are hereditary and are caused by abnormal genes passed from generations. According to the article "Lifestyle, Genetic Risk and Incidence of Cancer," published in the International Journal of Epidemiology in 2023, nearly 33% of cancer conditions that occur are hereditary, and the risk of genetic mutations is high in the disease. Hence, people are opting for genetic profiling for the early detection and personalized treatment of hereditary cancer cases. BRCA1 and BRCA2 are sometimes referred to as tumor suppressor genes. People who inherit the harmful variants of one of these genes are at a greater risk of several cancers, most notably breast and ovarian cancer, among other types. These people also tend to develop cancer at younger ages compared to people who do not have variations in the said genes. Studies focused on nucleic acid processing by cancer cells are likely to help understand cancer metabolism. DNA is typically packaged into a viral or non-viral particle to be transferred into the cell that is to be transfected. Gene transfer has been proposed as a new approach to enhance the effectiveness of antitumor drugs in treating intractable or metastatic cancers. The association of gene therapy and drugs (similar therapy) has been reported to strengthen the antiproliferative effects of classical treatments in lung, colorectal, pancreatic, bladder, and breast cancers, among others. Thus, the elevating economic burden of cancer bolsters the Asia Pacific transfection reagents and equipment market.

Asia Pacific Transfection Reagents and Equipment Market Overview

The Asia Pacific region is classified into China, Japan, India, South Korea, Australia and rest of Asia Pacific. China holds the largest market share in the year 2022. Asia Pacific countries such as China, India, Singapore and more with a well-established healthcare system as well as fast-growing pharmaceutical and medical industries. These countries have many healthcare facilities providing treatment and care services to cancer patients. According to an NIH study, yearly patient admissions in cancer hospitals in China climbed from 1.10 million to 3.24 million during 2010-2020. According to a study published in 2023 in the Journal of the American Medical Association, chronic kidney disease (CKD) prevalence in people aged 18 years or older in Mainland China is recorded at 8.2%. Moreover, the latest data from the International Agency for Research on Cancer (IARC) indicates that the estimated age-standardized rate (ASR) for stomach cancer in China is 21 per 100,000, and the crude rate is 33.06; for pancreatic cancer, the ASR is 5 per 100,000 with the crude rate of 8.6. As per the same source, the estimated number of new cases of stomach cancer and pancreatic cancer in people aged 0-74 in 2020 (for both sexes) was 478,508 and 124,994, respectively. Thus, the high burden of chronic diseases propels the demand for CGTs in China, in turn, fueling the transfection reagents and equipment market growth.

Asia Pacific Transfection Reagents and Equipment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Transfection Reagents and Equipment Market Segmentation

The Asia Pacific transfection reagents and equipment market is segmented based on product, method, application, end user, and country.

Based on product, the Asia Pacific transfection reagents and equipment market is bifurcated into reagents and instruments. The reagents segment held a larger share in 2022.

In terms of method, the Asia Pacific transfection reagents and equipment market is segmented into viral methods, non-viral methods, and hybrid methods. The non-viral methods segment held the largest share in 2022. The viral segment is subcategorized into retrovirus, adenovirus, adeno associated virus, and herpes virus. The non-viral segment is bifurcated into physical/mechanical method and chemical method. Further, the physical/mechanical method segment is subcategorized into electroporation, microinjection, biolistic method, laser method, magnetofection, and sonoporation. Also, the chemical method segment is subcategorized into liposomal based/high lipid and non-liposomal/high lipid based.

By application, the Asia Pacific transfection reagents and equipment market is segmented into biomedical research, protein production, and therapeutic delivery. The biomedical research segment held the largest share in 2022.

Based on end user, the Asia Pacific transfection reagents and equipment market is bifurcated into academics & research institutes and pharmaceutical & biotechnology companies. The academics & research institutes segment held a larger share in 2022.

Based on country, the Asia Pacific transfection reagents and equipment market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific transfection reagents and equipment market in 2022.

Fisher Scientific Inc, Promega Corp, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Mirus Bio LLC, QIAGEN NV, Merck KGaA, Lonza Group AG, MaxCyte Inc, and Polyplus-Transfection SA are some of the leading companies operating in the Asia Pacific transfection reagents and equipment market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Asia Pacific Transfection Reagents and Equipment Market - Key Market Dynamics

• 4.1 Asia Pacific Transfection Reagents and Equipment Market - Key Market Dynamics
• 4.2 Market Drivers
  • 4.2.1 Increasing Popularity of Cell and Gene Therapy
  • 4.2.2 Growing Economic Burden of Cancer
• 4.3 Market Restraints
  • 4.3.1 High Cost of Instruments and Consumables
• 4.4 Market Opportunities
  • 4.4.1 Ramping Up Small-Scale Processes to Large-Scale Processes
• 4.5 Future Trends
  • 4.5.1 Strategic Initiatives by Companies
• 4.6 Impact of Drivers and Restraints:

5. Transfection Reagents and Equipment Market - Asia Pacific Market Analysis

• 5.1 Asia Pacific Transfection Reagents and Equipment Market Revenue (US$ Million), 2022-2030
• 5.2 Asia Pacific Transfection Reagents and Equipment Market Forecast Analysis

6. Asia Pacific Transfection Reagents and Equipment Market Analysis - by Product

• 6.1 Reagents
  • 6.1.1 Overview
  • 6.1.2 Reagents: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
• 6.2 Equipment
  • 6.2.1 Overview
  • 6.2.2 Equipment: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Transfection Reagents and Equipment Market Analysis - by Modality

• 7.1 Viral
  • 7.1.1 Overview
  • 7.1.2 Viral: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.1.2.1 Retrovirus: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.1.2.2 Adenovirus: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.1.2.3 Adeno-Associated Virus: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.1.2.4 Herpes Virus: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
• 7.2 Non-Viral
  • 7.2.1 Overview
  • 7.2.2 Non-Viral: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.2.2.1 Physical/Mechanical Method: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.2.2.1.1 Electroporation: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.2.2.1.2 Microinjection: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.2.2.1.3 Biolistic Method: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.2.2.1.4 Laser Method: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.2.2.1.5 Magnetofection: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.2.2.1.6 Sonoporation: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.2.2.2 Chemical Method: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.2.2.2.1 Liposomal Based/High Lipid: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.2.2.2.2 Non-Liposomal Based/High Lipid: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
• 7.3 Hybrid
  • 7.3.1 Overview
  • 7.3.2 Hybrid: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Transfection Reagents and Equipment Market Analysis - by Application

• 8.1 Biomedical Research
  • 8.1.1 Overview
  • 8.1.2 Biomedical Research: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
• 8.2 Protein Production
  • 8.2.1 Overview
  • 8.2.2 Protein Production: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
• 8.3 Therapeutic Delivery
  • 8.3.1 Overview
  • 8.3.2 Therapeutic Delivery: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Transfection Reagents and Equipment Market Analysis - by End Users

• 9.1 Academic and Research Institutes
  • 9.1.1 Overview
  • 9.1.2 Academic and Research Institutes: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
• 9.2 Pharmaceutical and Biotechnological Companies
  • 9.2.1 Overview
  • 9.2.2 Pharmaceutical and Biotechnological Companies: Asia Pacific Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Transfection Reagents and Equipment Market -Country Analysis

• 10.1 Asia Pacific: Transfection Reagents and Equipment Market - Revenue and Forecast Analysis - by Country
  • 10.1.1 Asia Pacific: Transfection Reagents and Equipment Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.1 China: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.1.1 China: Transfection Reagents and Equipment Market Breakdown, by Product
      • 10.1.1.1.2 China: Transfection Reagents and Equipment Market Breakdown, by Modality
      • 10.1.1.1.2.1 China: Transfection Reagents and Equipment Market Breakdown, by Viral
      • 10.1.1.1.2.2 China: Transfection Reagents and Equipment Market Breakdown, by Non-Viral
      • 10.1.1.1.2.2.1 China: Transfection Reagents and Equipment Market Breakdown, by Physical/mechanical Method
      • 10.1.1.1.2.2.2 China: Transfection Reagents and Equipment Market Breakdown, by Chemical Method
      • 10.1.1.1.3 China: Transfection Reagents and Equipment Market Breakdown, by Application
      • 10.1.1.1.4 China: Transfection Reagents and Equipment Market Breakdown, by End Users
    • 10.1.1.2 Japan: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.2.1 Japan: Transfection Reagents and Equipment Market Breakdown, by Product
      • 10.1.1.2.2 Japan: Transfection Reagents and Equipment Market Breakdown, by Modality
      • 10.1.1.2.2.1 Japan: Transfection Reagents and Equipment Market Breakdown, by Viral
      • 10.1.1.2.2.2 Japan: Transfection Reagents and Equipment Market Breakdown, by Non-Viral
      • 10.1.1.2.2.2.1 Japan: Transfection Reagents and Equipment Market Breakdown, by Physical/mechanical Method
      • 10.1.1.2.2.2.2 Japan: Transfection Reagents and Equipment Market Breakdown, by Chemical Method
      • 10.1.1.2.3 Japan: Transfection Reagents and Equipment Market Breakdown, by Application
      • 10.1.1.2.4 Japan: Transfection Reagents and Equipment Market Breakdown, by End Users
    • 10.1.1.3 India: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.3.1 India: Transfection Reagents and Equipment Market Breakdown, by Product
      • 10.1.1.3.2 India: Transfection Reagents and Equipment Market Breakdown, by Modality
      • 10.1.1.3.2.1 India: Transfection Reagents and Equipment Market Breakdown, by Viral
      • 10.1.1.3.2.2 India: Transfection Reagents and Equipment Market Breakdown, by Non-Viral
      • 10.1.1.3.2.2.1 India: Transfection Reagents and Equipment Market Breakdown, by Physical/mechanical Method
      • 10.1.1.3.2.2.2 India: Transfection Reagents and Equipment Market Breakdown, by Chemical Method
      • 10.1.1.3.3 India: Transfection Reagents and Equipment Market Breakdown, by Application
      • 10.1.1.3.4 India: Transfection Reagents and Equipment Market Breakdown, by End Users
    • 10.1.1.4 South Korea: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.4.1 South Korea: Transfection Reagents and Equipment Market Breakdown, by Product
      • 10.1.1.4.2 South Korea: Transfection Reagents and Equipment Market Breakdown, by Modality
      • 10.1.1.4.2.1 South Korea: Transfection Reagents and Equipment Market Breakdown, by Viral
      • 10.1.1.4.2.2 South Korea: Transfection Reagents and Equipment Market Breakdown, by Non-Viral
      • 10.1.1.4.2.2.1 South Korea: Transfection Reagents and Equipment Market Breakdown, by Physical/mechanical Method
      • 10.1.1.4.2.2.2 South Korea: Transfection Reagents and Equipment Market Breakdown, by Chemical Method
      • 10.1.1.4.3 South Korea: Transfection Reagents and Equipment Market Breakdown, by Application
      • 10.1.1.4.4 South Korea: Transfection Reagents and Equipment Market Breakdown, by End Users
    • 10.1.1.5 Australia: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.5.1 Australia: Transfection Reagents and Equipment Market Breakdown, by Product
      • 10.1.1.5.2 Australia: Transfection Reagents and Equipment Market Breakdown, by Modality
      • 10.1.1.5.2.1 Australia: Transfection Reagents and Equipment Market Breakdown, by Viral
      • 10.1.1.5.2.2 Australia: Transfection Reagents and Equipment Market Breakdown, by Non-Viral
      • 10.1.1.5.2.2.1 Australia: Transfection Reagents and Equipment Market Breakdown, by Physical/mechanical Method
      • 10.1.1.5.2.2.2 Australia: Transfection Reagents and Equipment Market Breakdown, by Chemical Method
      • 10.1.1.5.3 Australia: Transfection Reagents and Equipment Market Breakdown, by Application
      • 10.1.1.5.4 Australia: Transfection Reagents and Equipment Market Breakdown, by End Users
    • 10.1.1.6 Rest of Asia Pacific: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.6.1 Rest of Asia Pacific: Transfection Reagents and Equipment Market Breakdown, by Product
      • 10.1.1.6.2 Rest of Asia Pacific: Transfection Reagents and Equipment Market Breakdown, by Modality
      • 10.1.1.6.2.1 Rest of Asia Pacific: Transfection Reagents and Equipment Market Breakdown, by Viral
      • 10.1.1.6.2.2 Rest of Asia Pacific: Transfection Reagents and Equipment Market Breakdown, by Non-Viral
      • 10.1.1.6.2.2.1 Rest of Asia Pacific: Transfection Reagents and Equipment Market Breakdown, by Physical/mechanical Method
      • 10.1.1.6.2.2.2 Rest of Asia Pacific: Transfection Reagents and Equipment Market Breakdown, by Chemical Method
      • 10.1.1.6.3 Rest of Asia Pacific: Transfection Reagents and Equipment Market Breakdown, by Application
      • 10.1.1.6.4 Rest of Asia Pacific: Transfection Reagents and Equipment Market Breakdown, by End Users

11. Transfection Reagents and Equipment Market -Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in The Transfection Reagents and Equipment Market, 2020-2023
• 11.3 Inorganic Growth Strategies
  • 11.3.1 Overview
• 11.4 Organic Growth Strategies
  • 11.4.1 Overview

12. Company Profiles

• 12.1 Thermo Fisher Scientific Inc
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Promega Corp
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 F. Hoffmann-La Roche Ltd
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Bio-Rad Laboratories Inc
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 Mirus Bio LLC
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 QIAGEN NV
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 Merck KGaA
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 Lonza Group AG
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 MaxCyte Inc
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments

13. Appendix

• 13.1 About Us

관련자료